Bluejay Diagnostics is a pre-revenue, development-stage medical diagnostics company building a rapid point-of-care diagnostic platform called Symphony, targeting critical care settings like ICUs and ERs. Symphony has two components: a compact portable analyzer that processes whole blood using centrifugal force, and single-use disposable test cartridges containing all necessary reagents. A clinician adds a few drops of blood, inserts the cartridge, and gets a quantitative result in about 20 minutes. Each analyzer can run up to six cartridges simultaneously. Bluejay's only product candidate is the Symphony IL-6 test, which measures interleukin-6, an inflammatory biomarker used to assess infection severity and predict 28-day mortality risk in ICU sepsis patients. Bluejay's intended business model follows the classic razor-and-blades approach: place analyzers in hospitals with financing options to lower upfront barriers, then generate recurring revenue through single-use cartridge sales. Bluejay also plans to expand the Symphony test menu over time to include cardiac biomarkers, which would drive more cartridge consumption per customer. The company has no FDA clearance and no commercial products. Key near-term milestones include completing enrollment in its SYMON-II pivotal clinical trial, verifying cartridge manufacturing with its contract manufacturer Sanyoseiko, and targeting a 510(k) submission to the FDA in 2027. Bluejay has no revenue, has an accumulated deficit of roughly $41.5M, and needs to raise at least $20M to execute its current plan.